Literature DB >> 24723594

Immunotherapy: it takes a village.

Drew Pardoll1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24723594      PMCID： PMC4792256          DOI： 10.1126/science.344.6180.149-a

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  14 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Identification of the components of the murine T cell antigen receptor complex.

Authors:  L E Samelson; J B Harford; R D Klausner
Journal:  Cell       Date:  1985-11       Impact factor: 41.582

3.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

4.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

5.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

6.  A new member of the immunoglobulin superfamily--CTLA-4.

Authors:  J F Brunet; F Denizot; M F Luciani; M Roux-Dosseto; M Suzan; M G Mattei; P Golstein
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

7.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

8.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.

Authors:  P S Linsley; W Brady; L Grosmaire; A Aruffo; N K Damle; J A Ledbetter
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

9.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307
View more
  9 in total

1.  Trial watch: Naked and vectored DNA-based anticancer vaccines.

Authors:  Norma Bloy; Aitziber Buqué; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-04-02       Impact factor: 8.110

Review 2.  Novel vaccines for glioblastoma: clinical update and perspective.

Authors:  Evan K Winograd; Michael J Ciesielski; Robert A Fenstermaker
Journal:  Immunotherapy       Date:  2016-11       Impact factor: 4.196

Review 3.  Charting roadmaps towards novel and safe synergistic immunotherapy combinations.

Authors:  Miguel F Sanmamed; Pedro Berraondo; Maria E Rodriguez-Ruiz; Ignacio Melero
Journal:  Nat Cancer       Date:  2022-06-28

4.  mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.

Authors:  Mariola Fotin-Mleczek; Kai Zanzinger; Regina Heidenreich; Christina Lorenz; Aleksandra Kowalczyk; Karl-Josef Kallen; Stephan M Huber
Journal:  Radiat Oncol       Date:  2014-08-15       Impact factor: 3.481

Review 5.  PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.

Authors:  Jun Wang; Ruirong Yuan; Wenru Song; Jingwei Sun; Delong Liu; Zihai Li
Journal:  J Hematol Oncol       Date:  2017-01-25       Impact factor: 17.388

6.  In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction.

Authors:  Chih-Hao Lu; Wei-Min Chung; Chun-Hao Tsai; Ju-Chien Cheng; Kai-Cheng Hsu; Huey-En Tzeng
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.996

7.  Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.

Authors:  Howard L Kaufman; Lisa H Butterfield; Pierre G Coulie; Sandra Demaria; Robert L Ferris; Jérôme Galon; Samir N Khleif; Ira Mellman; Pamela S Ohashi; Willem W Overwijk; Suzanne L Topalian; Francesco M Marincola
Journal:  J Immunother Cancer       Date:  2016-06-21       Impact factor: 13.751

Review 8.  Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy.

Authors:  Chongxian Pan; Hongtao Liu; Elizabeth Robins; Wenru Song; Delong Liu; Zihai Li; Lei Zheng
Journal:  J Hematol Oncol       Date:  2020-04-03       Impact factor: 17.388

9.  Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer.

Authors:  Julian L Goggi; Siddesh V Hartimath; Tan Yun Xuan; Shivashankar Khanapur; Beverly Jieu; Hui Xian Chin; Boominathan Ramasamy; Peter Cheng; Tang Jun Rong; Yong Fui Fong; Tsz Ying Yuen; Rasha Msallam; Ann-Marie Chacko; Laurent Renia; Charles Johannes; You Yi Hwang; Edward G Robins
Journal:  Mol Imaging Biol       Date:  2021-03-12       Impact factor: 3.488
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.